[
By ELIZABETH
MACDONALD
Staff
Reporter of THE WALL STREET JOURNAL
Investors in
stocks of high-tech and pharmaceutical
companies,
beware: A study warns that a growing number of
the
companies are using an obscure accounting rule that
some critics
say can inflate subsequent earnings
artificially.
The authors
of the report say that 3Com, Novell and Exar
have already
benefited from the rule. While all three
companies
acknowledge using the bookkeeping method, they
say it is
mandated by accounting rules, and hasn't
distorted
their profits.
------------------------------------------------------------
Charged-Up
Earnings
Here's how
accounting expert Baruch Lev of New York
University
says acquisition charges for "in process"
research and
development can pump-up subsequent high-tech
earnings.
The companies defend their accounting as proper.
Cost of Size
ofTime Fiscal FY '96
Acquisitions
ChargesPeriod of
1996 Net
Acquisitions Earnings Without
Immediate
Charges*
3Com $220.0 $192.9 1/94-10/94 $177.9 $144.8
Novell
529.7
425.9 6/93-6/94 126.0 19.5
Exar 24.1 16.9 5/94-6/94 13.6 10.4
Dollar
figures are in millions
*Assumes
four-year write-off of R&D costs starting at least
four
quarters after acquisition, instead of immediate
write-off.
------------------------------------------------------------
The March
1997 study by Baruch Lev, an accounting and
finance
professor at New York University, and Zhen Deng, an
NYU graduate
student in accounting, found an increasing
number of
companies using the 22-year-old rule.
The rule in
question lets an acquiring company set a value
for the
"in-process" research and development assets at an
acquired
company, and immediately write off that amount.
The higher
the value, the more acquirers can avoid hits to
future
earnings from goodwill. That's because any goodwill
-- the
premium of the purchase price over the acquired
company's
book value -- is supposed to be deducted from the
acquirer's
profits over periods as long as 40 years.
Jack
Ciesielski, editor of the Analyst's Accounting
Observer, a
Baltimore publication for stock analysts,
warns,
"Investors should be careful of subsequent earnings
posted by
acquirers using this rule, because they are a bit
jazzed."
Gabrielle
Napolitano, a securities analyst who follows
accounting
issues at Goldman Sachs, holds a similar
opinion:
"Acquiring companies may be assigning too high a
value to
this in-process R&D, distorting subsequent
earnings."
The practice
is on the rise. The study says that only three
companies
wrote off part of their acquisitions as
"in-process" R&D during the 1980s. But 389 have
done so in
the 1990s, a
record 156 last year alone. Nearly 40% of the
acquisitions
occurred at computer-software and equipment
companies,
the rest at pharmaceutical and biotech concerns.
To be sure,
companies must take such write-offs to comply
with
accounting standards. "The companies are not doing
anything
wrong," says Mr. Lev. "But what is wrong is the
accounting
system that allows these immediate write-offs."
The authors
say investors should watch out for euphemisms
for this
acquired R&D, such as "incomplete technology,"
"in-process engineering and development," or
"acquired
technology
rights."
A computer
search by Mr. Lev and Ms. Deng found 392
acquisitions
using such a write-off between 1980 to 1996.
The average
R&D write-off was a whopping 72% of the entire
purchase
price. The size of the write-offs, the authors
say, caused
more than 75% of companies in the sample to
post a loss
for that quarter.
After that,
the authors calculate, the write-offs gave a
temporary
22% kick on average to the acquiring companies'
earnings in
the fourth quarter after the acquisitions.
Reason: If
they hadn't taken the immediate write-offs for
the R&D,
the acquirers would have had to count the R&D
costs as
expenses over four years -- which Mr. Lev
estimates is
about the average life of R&D software --
which would
have reduced their earnings over that period.
"Managers love this write-off because it inflates future
earnings," says Mr. Lev.
Moreover,
the authors estimate the write-offs temporarily
overstated
the acquiring companies' return on equity by an
average 37%
in the year after the write-off. That can put a
smile on the
faces of corporate executives, because return
on equity is
a yardstick used by compensation committees to
set
executive pay, according to William M. Mercer Inc., a
New York
compensation consulting firm.
The impact
on earnings can be substantial.
In 1994,
3Com, Santa Clara, Calif., wrote off $192.9
million, or
88% of its total $220 million acquisition price
for four
companies, including Synernetics and Nice Com. Mr.
Lev
estimates that by the fiscal year ended May 1996,
3Com's
write-offs had boosted its annual earnings by 23%
over the
level that would have been reported if the
acquired
R&D had been written off over four years.
Alan Groves,
3Com's corporate controller, said Mr. Lev used
"highly
fallacious" assumptions, and that 3Com's accounting
was
"conservative." But he wouldn't elaborate.
Another case
in point: Novell of Provo, Utah. Between June
1993 and
1994, this maker of network software wrote off as
"in-process" research and development $425.9
million, or
80% of its
total $529.7 million price tag for four
acquisitions
-- Unix Systems Lab, Serius, Fluent and
Borland
International's Quattro Pro, a spreadsheet program.
Novell
eventually sold much of Unix's software line and
Quattro Pro.
Mr. Lev says
that if Novell had written off the R&D
expenses
over four years, its net income would have been
$19.5
million in the year ended October 1996, less than
one-sixth of
the $126 million it actually reported.
Novell's
director of investor relations, Peter Troop, says,
"Novell
accounted for its acquisitions as required by
generally
accepted accounting principles."
Exar also
wrote off $16.9 million in acquired R&D for two
companies it
bought between May 1994 and June 1994. By the
end of the
fiscal year ended in March 1996, this Fremont,
Calif.,
telecommunications company reported $13.6 million
in net
income. But Mr. Lev says if it had written the R&D
off over
four years, its net would have been $10.4 million.
So the
R&D charges boosted net by 31%. Ron Guire, chief
financial
officer of Exar, remarks, "It's a nice study for
a college,
but in practice I think it's crazy."
Mr.
Ciesielski says the sheer size of some of the R&D
write-downs
indicates that some acquiring companies are
abusing the
rules by including too much goodwill. But most
companies
don't release the details of the calculations
they use to
arrive at the write-down amounts. Companies
wouldn't
have to worry about the size of their goodwill
write-downs
if they used "pooling-of-interest" accounting;
but
companies that use that method for an acquisition can't
quickly
dispose of unwanted assets.
So far, both
the Financial Accounting Standards Board, the
chief
accounting rulemaking body, and the Securities and
Exchange
Commission say they are looking into the
controversy.
But little action has been taken to date.
Determining
whether R&D write-offs were appropriate in
hindsight is
complicated by the fact that, as Bear Stearns
accounting
expert Pat McConnell notes, "no reliable data on
R&D cash
flows postacquisition exist because such revenue
is typically
commingled with a firm's other earnings."
Adds Mr.
Ciesielski: "If these write-offs are in fact all
R&D, the
companies should be generating phenomenal revenues
and new
products -- but are they?"
* * *
BUFFETT AT
THE BAT: At the Berkshire Hathaway Inc. annual
meeting
Monday, billionaire investor and Salomon Inc.
stockholder
Warren Buffett said the "odds are overwhelming"
that he'll
convert some of his Salomon preferred-stock
holdings
into the common stock of the securities firm this
year, rather
than cash out.
In 1995, in
what was seen as a no-confidence vote for
Salomon's
management, Mr. Buffett chose to take cash for
some of his
preferred stock, but, last year, Mr. Buffett
decided to
convert a $140 million chunk of preferred into
Salomon
common stock. Mr. Buffett can convert his preferred
stock into
common shares at $38 apiece, well below
Salomon's
current price of $52.625.
When asked
about his plans, Mr. Buffett at first hedged a
bit, saying,
"We see no reason to swing at the ball when
it's still
in the pitcher's glove." Mr. Buffett doesn't
have to
decide whether to convert or not this year until
the fall.
-- Anita
Raghavan
[Image]
[Image]
-----
[Image]
[Image]
[Image]
[Image]
Return to top of page
[Toolbar]
[Dow
Jones Logo]
Copyright © 1997 Dow Jones & Company, Inc. All Rights Reserved.